Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 41
Filter
1.
Rev. argent. microbiol ; 48(1): 57-61, mar. 2016. graf
Article in Spanish | LILACS | ID: biblio-1283538

ABSTRACT

Se evaluó la actividad in vitro de la asociación entre ampicilina y ceftriaxona frente a 30 aislamientos de Enterococcus faecalis obtenidos de infecciones invasivas de pacientes atendidos en el Hospital de Clínicas José de San Martín, Ciudad Autónoma de Buenos Aires. Las sinergias entre ampicilina y ceftriaxona se determinaron mediante la técnica de dilución en caldo Müeller-Hinton con el agregado de diferentes concentraciones subinhibitorias de ceftriaxona o sin este. La asociación fue sinérgica en 22/30 aislamientos. En 14/30 aislamientos la asociación disminuyó los valores de concentración inhibitoria mínima (CIM) y de concentración bactericida mínima (CBM); en 6/30 se observó solamente una disminución de la CIM, mientras que en 2 solo se determinó una reducción de la CBM. La actividad bactericida de la asociación fue mayor a bajas concentraciones de ampicilina (menor de 1µg/ml). Se demostró la sinergia in vitro entre ampicilina-ceftriaxona; se confirmó así la utilidad de esta asociación en el tratamiento de infecciones severas causadas por E. faecalis


In vitro activity of the combination of ampicillin- ceftriaxone against 30 Enterococcus faecalis isolates recovered from invasive infections in patients admitted to Hospital de Clínicas José de San Martin in the city of Buenos Aires was assessed. Ampicillin- ceftriaxone synergies were determined by microdilution in Müeller-Hinton (MH) broth with and without subinhibitory concentrations of ceftriaxone. Synergy was detected in 22/30 isolates. A decrease in both minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) was observed in 14/30 isolates, whereas in 6/30 isolates the decrease was observed in the MIC value and only in the MBC value in the 2 remaining isolates. The bactericidal activity of the combination showed to be higher at low concentrations of ampicillin (< 1µg/ml). We detected in vitro synergy using the ampicillin-ceftriaxone combination and thus, its efficacy was confirmed in the treatment of severe infections by E. faecalis


Subject(s)
Humans , Male , Female , Ceftriaxone/pharmacology , Microbial Sensitivity Tests/statistics & numerical data , Enterococcus faecalis/isolation & purification , Ampicillin/pharmacology , Anti-Bacterial Agents/analysis , Bacterial Infections/drug therapy , In Vitro Techniques/methods , Drug Synergism
3.
Journal of Korean Medical Science ; : 715-723, 2016.
Article in English | WPRIM | ID: wpr-195408

ABSTRACT

In Republic of Korea, a 7-valent pneumococcal conjugated vaccine (PCV7) was licensed for use in infants in 2003, and 13-valent PCV (PCV13) replaced it since 2010. We investigated trends in serotype distribution and antibiotic susceptibility of pneumococcal isolates from adult patients with invasive pneumococcal diseases (IPD). Invasive pneumococcal isolates from adult patients of ≥ 16 years of age were collected from 1997 to 2012. Serotypes of the isolates were determined by the Quellung reaction. Distribution of serotypes was analyzed according to the vaccine types. Antibiotic susceptibility was tested by using E-test strips. A total of 272 invasive pneumococcal isolates were included. The most common serotypes were serotype 19F (8.5%, 23/272), and serotype 3 (8.1%, 22/272), and 24.6% (67/272) of the isolates were of non-vaccine serotypes. Of the 272 isolates, 2.6% (7/272) were penicillin MICs of ≥ 4 µg/mL. The proportion of the PCV13 serotypes decreased from 63.3% (50/79) in 1997-2003 to 48.6% (17/35) in 2011-2012, whereas that of non-vaccine serotypes was 26.6% (21/79) and 25.7% (9/35), respectively, for the same periods. The proportion of the PCV13 serotypes showed a decreasing trend among adult patients with IPD over the study period.


Subject(s)
Adolescent , Adult , Aged , Female , Humans , Male , Middle Aged , Young Adult , Anti-Infective Agents/pharmacology , Ceftriaxone/pharmacology , Microbial Sensitivity Tests , Penicillins/pharmacology , Pneumococcal Infections/drug therapy , Republic of Korea , Serogroup , Serotyping , Streptococcus pneumoniae/drug effects
4.
Yonsei Medical Journal ; : 350-357, 2016.
Article in English | WPRIM | ID: wpr-147355

ABSTRACT

PURPOSE: The detection of high-level tetracycline-resistant strains of Neisseria gonorrhoeae (TRNG) can make important epidemiological contributions that are relevant to controlling infections from this pathogen. In this study, we aimed to determine the incidence of TRNG isolates over time and also to investigate the characteristics and genetic epidemiology of these TRNG isolates in Korea. MATERIALS AND METHODS: The antimicrobial susceptibilities of 601 isolates of N. gonorrhoeae from 2004 to 2011 were tested by standard Clinical and Laboratory Standards Institute methods. To determine the molecular epidemiological relatedness, N. gonorrhoeae multi-antigen sequence typing was performed. RESULTS: The incidence of TRNG increased from 2% in 2004 to 21% in 2011. The minimum inhibitory concentration distributions of ceftriaxone and susceptibility of ciprofloxacin in TRNG were different from non-TRNG and varied according to the year of isolation. Most of the TRNG isolates collected from 2004 to 2007 exhibited genetic relatedness, with sequence type (ST) 1798 being the most common. From 2008 to 2011, the STs of the isolates became more variable and introduction of genetically unrelated TRNG were noted. CONCLUSION: The increased incidence of TRNG strains until 2007 appears to be due, at least in part, to clonal spread. However, we propose that the emergence of various STs since 2008 could be associated with foreign import.


Subject(s)
Humans , Anti-Bacterial Agents/pharmacology , Ceftriaxone/pharmacology , Ciprofloxacin/pharmacology , DNA, Bacterial/analysis , Drug Resistance, Multiple, Bacterial/genetics , Gonorrhea/drug therapy , Incidence , Microbial Sensitivity Tests , Molecular Epidemiology , Neisseria gonorrhoeae/drug effects , Republic of Korea/epidemiology , Sequence Analysis, DNA , Tetracycline/pharmacology , Tetracyclines/pharmacology
5.
Braz. j. infect. dis ; 18(5): 512-517, Sep-Oct/2014. tab, graf
Article in English | LILACS | ID: lil-723083

ABSTRACT

Since antimicrobial resistance among uropathogens against current first line agents has affected the management of severe urinary tract infection, we determined the likelihood that antibiotic regimens achieve bactericidal pharmacodynamic exposures using Monte Carlo simulation for five antimicrobials (ciprofloxacin, ceftriaxone, piperacillin/tazobactam, ertapenem, and meropenem) commonly prescribed as initial empirical treatment of inpatients with severe community acquired urinary tract infections. Minimum inhibitory concentration determination by Etest was performed for 205 Brazilian community urinary tract infection Escherichia coli strains from 2008 to 2012 and 74 E. coli bloodstream strains recovered from a surveillance study. Pharmacodynamic exposure was modeled via a 5000 subject Monte Carlo simulation. All isolates were susceptible to ertapenem and meropenem. Piperacillin/tazobactam, ceftriaxone and ciprofloxacin showed 100%, 97.5% and 83.3% susceptibility among outpatient isolates and 98.6%, 75.7% and 64.3% among inpatient isolates, respectively. Against outpatient isolates, all drugs except ciprofloxacin (82.7% in aggressive and 77.6% in conservative scenarios) achieved high cumulative fraction of response: car-bapenems and piperacillin/tazobactam cumulative fraction of responses were close to 100%, and ceftriaxone cumulative fraction of response was 97.5%. Similar results were observed against inpatients isolates for carbapenems (100%) and piperacillin/tazobactam (98.4%), whereas ceftriaxone achieved only 76.9% bactericidal cumulative fraction of response and ciprofloxacin 61.9% (aggressive scenario) and 56.7% (conservative scenario) respectively. Based on this model, standard doses of beta-lactams were predicted to deliver sufficient pharmacodynamic exposure for outpatients. However, ceftriaxone should be avoided for inpatients and ciprofloxacin empirical prescription should be avoided in both inpatients and outpatients with complicated urinary tract infection.


Subject(s)
Humans , Anti-Bacterial Agents/pharmacology , Escherichia coli/drug effects , Anti-Bacterial Agents/pharmacokinetics , Ceftriaxone/pharmacokinetics , Ceftriaxone/pharmacology , Ciprofloxacin/pharmacokinetics , Ciprofloxacin/pharmacology , Escherichia coli Infections/drug therapy , Escherichia coli Infections/microbiology , Escherichia coli/isolation & purification , Monte Carlo Method , Microbial Sensitivity Tests/methods , Penicillanic Acid/analogs & derivatives , Penicillanic Acid/pharmacokinetics , Penicillanic Acid/pharmacology , Piperacillin/pharmacokinetics , Piperacillin/pharmacology , Pyelonephritis/microbiology , Severity of Illness Index , Thienamycins/pharmacokinetics , Thienamycins/pharmacology , Urinary Tract Infections/drug therapy , Urinary Tract Infections/microbiology , beta-Lactams/pharmacokinetics , beta-Lactams/pharmacology
7.
Article in English | IMSEAR | ID: sea-156323

ABSTRACT

Background. In the past, Neisseria gonorrhoeae has developed resistance to antimicrobial agents used for its treatment. Consequently, extended-spectrum cephalosporins form the mainstay of treatment for gonorrhoea. Methods. Samples from 88 patients attending the sexually transmitted diseases clinics from December 2009 to January 2011 in two referral hospitals in New Delhi were studied. Antimicrobial susceptibility testing was done using the disc diffusion method as per the calibrated dichotomous sensitivity technique against the following antibiotics: penicillin (0.5 i.u.), tetracycline (10 μg), nalidixic acid (30 μg), ciprofloxacin (1 μg), spectinomycin (100 μg), ceftriaxone (0.5 μg) and cefpodoxime (10 μg) (Oxoid UK). Azithromycin (15 μg) (Oxoid, UK) was tested as per the guidelines of the Clinical and Laboratory Standards Institute. Minimum inhibitory concentrations were determined using the Etest for penicillin, tetracycline, ciprofloxacin, ceftriaxone, spectinomycin and azithromycin as per the manufacturer’s instruction (Biomerieux, France). Results. Eighteen isolates of Neisseria gonorrhoeae were obtained. Three of these had decreased susceptibility to ceftriaxone and cefpodoxime by the disc diffusion method. The minimum inhibitory concentrations of ceftriaxone for two isolates were 0.064 μg/ml and for one isolate it was 0.125 μg/ml. Conclusion. Higher minimum inhibitory concentrations to extended-spectrum cephalosporins is of concern as it has been shown to precede treatment failure. This may warrant its use in increased/multiple dosages alone or possibly in combination (dual therapy), thereby complicating effective disease control. Our report is in accordance with earlier reports from different parts of the world. Therefore, a continuous surveillance of antimicrobial resistance is crucial to tailor treatment schedules for Neisseria gonorrhoeae in a particular geographical region.


Subject(s)
Anti-Bacterial Agents/pharmacology , Ceftizoxime/analogs & derivatives , Ceftizoxime/pharmacology , Ceftriaxone/pharmacology , Ciprofloxacin/pharmacology , India , Microbial Sensitivity Tests , Nalidixic Acid/pharmacology , Neisseria gonorrhoeae/drug effects , Neisseria gonorrhoeae/isolation & purification , Penicillins/pharmacology , Spectinomycin/pharmacology , Tetracycline/pharmacology
8.
Rev. argent. microbiol ; 44(1): 30-35, mar. 2012. graf, tab
Article in Spanish | LILACS | ID: lil-639715

ABSTRACT

Los objetivos de este estudio fueron determinar la actividad in vitro de las cefalosporinas de espectro extendido frente a aislamientos clínicos de enterobacterias sin AmpC inducible y evaluar la utilidad de las normativas propuestas por el CLSI 2009 y de los puntos de corte recomendados por el CLSI 2010 y el EUCAST 2010. El análisis incluye la caracterización feno y genotípica de los mecanismos de resistencia. En todos los aislamientos se realizó un antibiograma semicuantitativo y se determinó la CIM por dilución en agar. Asimismo, se realizó la detección fenotípica de p-lactamasas de espectro extendido (BLEE), de AmpC plasmídica (AmpCp) y de carbapenemasas de tipo KPC. En los aislamientos que fueron resistentes a las cefalosporinas de espectro extendido (CEE) se evaluó, mediante PCR múltiple para b/aSHV y b/aCTX-M y PCR con cebadores específicos, el tipo de p-lactamasa pre-valente y la presencia de KPC. Se recuperaron de pacientes 169 aislamientos resistentes a CEE: 95 de K/ebsie//a pneumoniae, 55 de Escherichia co/i y 19 de Proteus mirabi/is. La resistencia a CEE se verificó en el 56,2 %; 32,6 % y 11,2 % de estos conjuntos de aislamientos, respectivamente. Se detectó el fenotipo BLEE en 152 aislamientos (90 %), el fenotipo AmpCp en 12 (7 %) y el KPC en 5 (3 %). Las recomendaciones del CLSI 2009 y los puntos de corte del CLSI 2010 y del EUCAST 2010 para la ceftriaxona permitieron detectar eficientemente las BLEE, mientras que para la ceftacidima, con los puntos de corte del CLSI 2010 solo se detectó el 55 % de las BLEE. Esta discrepancia en los porcentajes de resistencia a ceftriaxona y a ceftacidima se relaciona con la presencia de CTX-M en nuestro medio. Los nuevos puntos de corte detectaron con mayor eficiencia las enzimas de tipo AmpCp.


The aims of this study were to evaluate the in vitro activity of extended-spectrum cephalosporins (ESC) in non-inducible AmpC enterobacteria throµgh phenotypic and genotypic characterization of the mechanisms of resistance (ESBL, plasmid-mediated AmpC and KPC) and to evaluate the interpretation criteria proposed by the existing recommendations and the new breakpoints established by the CLSI and the EUCAST. Susceptibility tests and PCR multiplex for b/aSHV and b/aCTX-M and amplification using specific primers was performed. One hundred sixty nine resistant isolates: K/ebsie//a pneumoniae (95), Escherichia co/i (55), and Proteus mirabi/is (19) were recovered. ESC resistance was 56.2 %, 32.6%, and 11.2 %, respectively. ESBL was detected in 152 (90 %) isolates, plasmid-mediated AmpC in 12 (7 %) and KPC in 5 (3 %). The CLSI 2009 recommendations and the breakpoints sµggested by the CLSI 2010 and the EUCAST for ceftriaxone were efficacious to detect ESBL, whereas the different breakpoints for ceftazidime presented discrepancies. The CLSI 2010 breakpoints only detected 55 % of the ESBL-producing isolates due to the endemic presence of CTX-M ESBLs in our country. Regarding the plasmid-mediated AmpC producers, the recommendations of the CLSI 2010 and the EUCAST 2010 proved to be more efficient than the old ones.


Subject(s)
Humans , Anti-Bacterial Agents/pharmacology , Bacterial Proteins/genetics , Cephalosporins/pharmacology , Drug Resistance, Multiple, Bacterial/genetics , Escherichia coli/drug effects , Klebsiella pneumoniae/drug effects , Microbial Sensitivity Tests/standards , Proteus mirabilis/drug effects , beta-Lactamases/genetics , Ceftazidime/pharmacology , Ceftriaxone/pharmacology , Escherichia coli Infections/microbiology , Escherichia coli Proteins/genetics , Escherichia coli/enzymology , Escherichia coli/genetics , Escherichia coli/isolation & purification , Klebsiella Infections/microbiology , Klebsiella pneumoniae/enzymology , Klebsiella pneumoniae/genetics , Klebsiella pneumoniae/isolation & purification , Prospective Studies , Proteus Infections/microbiology , Proteus mirabilis/enzymology , Proteus mirabilis/genetics , Proteus mirabilis/isolation & purification , Societies, Scientific/standards
9.
Int. braz. j. urol ; 38(1): 25-32, Jan.-Feb. 2012. graf, tab
Article in English | LILACS | ID: lil-623311

ABSTRACT

Urinary tract infections (UTI) are one of the most common infections with an increasing resistance to antimicrobial agents. PURPOSE: Empirical initial antibiotic treatment of UTI must rely on susceptible data from local studies. MATERIALS AND METHODS: Retrospective analysis of isolated bacteria from children with UTIs was performed at the university hospital during years 2006-2009. The findings were compared with data collected in a similar study carried out in 2002- 2003. RESULTS: A total of 1439 uropathogens were isolated. Escherichia coli (E.coli) was the leading cause, followed by Enterobacter, and other gram negative bacilli. It was observed resistance of E.coli to ceftriaxone, cefexime, amikacin, gentamycin, and nalidixic acid; Enterobacter to cefexime; and the resistance of gram negative bacilli to gentamicin and cefexime increased significantly. The highest effective antibiotic was Imipenem, ciprofloxacin, and amikacin with 96.7%, 95% and 91% sensitivity rates , respectively, followed by ceftriaxone 77.2%, gentamicin 77%, nitrofurantoin 76.4%, nalidixic acid 74.3% and cefexime with 70%. CONCLUSION: The use of nitrofurantoin or nalidixic acid as initial empirical antibacterial therapy for cystitis seems appropriate. For cases of simple febrile UTI, the use of initial parenteral therapies with amikacin or ceftriaxone followed by an oral third generation cephalosporin also seemed appropriated, and in cases of severely ill patients or complicated UTI, imipenem as monotherapy or, a combination of Ceftriaxone with an aminoglycoside, are recommended.


Subject(s)
Child , Child, Preschool , Humans , Infant , Infant, Newborn , Anti-Bacterial Agents/pharmacology , Bacterial Infections/drug therapy , Drug Resistance, Multiple, Bacterial/drug effects , Urinary Tract Infections/drug therapy , Urinary Tract Infections/microbiology , Amikacin/pharmacology , Ceftriaxone/pharmacology , Ciprofloxacin/pharmacology , Cystitis/microbiology , Enterobacter/drug effects , Escherichia coli/drug effects , Escherichia coli/isolation & purification , Microbial Sensitivity Tests , Nalidixic Acid/pharmacology , Nitrofurantoin/pharmacology , Retrospective Studies
10.
Professional Medical Journal-Quarterly [The]. 2012; 19 (4): 482-487
in English | IMEMR | ID: emr-145964

ABSTRACT

To compare the efficacy of ciprofloxacin with ceftriaxone in the treatment of spontaneous bacterial peritonitis in patients with cirrhosis liver and ascites. This hospital based quasi-experimental study. Department of Medicine, Khyber Teaching Hospital Peshawar. October, 2009 to April, 2010. A total of 200 patients were selected by non-probability purposive sampling method after obtaining an informed consent. Sample size was calculated through WHOS statistical calculator. All the selected patients had clinical and biochemical evidence of cirrhosis liver and spontaneous bacterial peritonitis. Both sexes were included in the selected patients had clinical and biochemical evidence of cirrhosis liver and spontaneous bacterial peritonitis. Both sexes were included in the study. They were randomly divided into two groups; group I was treated with ciprofloxacin and group II was treated with ceftriaxone. 200 patients including 124 males and 76 females with spontaneous bacterial peritonitis were included in the study. 100 patients each were treated with ciprofloxacin and ceftriaxone in the two groups. 82% responded favourably to 5 days course of I/V 200 mg ciprofloxacin and 91% were cured with 5 days therapy of I/V 2gm ceftriaxone. Both ceftriaxone and ciprofloxacin are equally effective in the treatment of spontaneous bacterial peritonitis


Subject(s)
Humans , Male , Female , Ascites/complications , Liver Cirrhosis/complications , Ciprofloxacin/pharmacology , Ceftriaxone/pharmacology , Treatment Outcome
12.
Oman Medical Journal. 2011; 26 (1): 43-47
in English | IMEMR | ID: emr-112849

ABSTRACT

To determine the prevalent serotypes of Streptococcus pneumoniae and the rate of penicillin-nonsusceptibility among pneumococci in Oman. Pneumococcal isolates encountered during the period of September 2002 to December 2007 in the Royal Hospital were serotyped. Clinical information as well as the penicillin susceptibility reports were retrieved from the hospital information system and medical records, 120 strains of Streptococcus pneumoniae were isolated of which 85 strains were seroptyped. 20 different serotypes were identified; the most common seroptypes were 9A, 6B, 19F, 14 and 23F. 56% of the strains were not susceptible to pencillin, while 99% of these were susceptible to ceftriaxone. 74.3% and 46.1% of the serotypes are covered by the pneumococcal polysaccharide vaccine and the 7-valent pneumococcal conjugate vaccine respectively, Certain few pneumococcal serotypes such as 9A, 6B and 19F are more prevalent in the Omani community than others. More than half of S. pneumoniae are not susceptible to penicillin while the great majority of the strains are susceptible to ceftriaxone


Subject(s)
Serotyping , Streptococcus pneumoniae/classification , Penicillin Resistance/genetics , Microbial Sensitivity Tests , Streptococcus pneumoniae/isolation & purification , Ceftriaxone/pharmacology , Drug Resistance, Bacterial
13.
Indian J Med Sci ; 2010 Dec; 64(12) 556-559
Article in English | IMSEAR | ID: sea-145579

ABSTRACT

Shigellosis is a disease of public health importance in developing countries. It may cause self-limited diarrhea to severe dysentery. Emergence of multi drug resistant (MDR) strains is a growing concern globally. Ceftriaxone and ciprofloxacin are the drugs of choice for MDR cases. Here, we report a case of MDR Shigella flexneri from an immunocompromised patient. The strain was resistant to ceftriaxone [minimum inhibitory concentration (MIC) ≥ 64 μg/ml], limiting the treatment option. Simultaneously, the strain was also found to be resistant to ciprofloxacin (MIC ≥ 4 μg/ml). However, it was susceptible to ceftazidime (MIC 4 μg/ml). This is the first case of ceftriaxone resistant Shigella spp. reported from our hospital.


Subject(s)
Anti-Bacterial Agents/pharmacology , Anti-Bacterial Agents/therapeutic use , Ceftazidime/pharmacology , Ceftazidime/therapeutic use , Ceftriaxone/pharmacology , Ceftriaxone/therapeutic use , Drug Resistance, Bacterial , Dysentery, Bacillary/diagnosis , Dysentery, Bacillary/drug therapy , Dysentery, Bacillary/immunology , Female , Humans , Immunocompromised Host , Microbial Sensitivity Tests , Middle Aged , Shigella flexneri/drug effects
14.
J. pediatr. (Rio J.) ; 84(3): 276-280, May-June. 2008. tab
Article in English, Portuguese | LILACS, SES-SP | ID: lil-485287

ABSTRACT

OBJETIVO: Doença Invasiva Pneumocócica (DPI) afeta crianças principalmente menores de 5 anos, idosos e grupos de risco, especialmente pessoas infectadas pelo vírus da Imunodeficiência Humana (HIV). O objetivo deste trabalho foi analisar as doenças pneumocócicas invasivas (DPI) em crianças e adolescentes infectados pelo vírus da imunodeficiência humana (HIV), de acordo com morbiletalidade, sorotipos, sensibilidade à penicilina e ceftriaxona e distribuição de Streptococcus pneumoniae (Sp) sensíveis e resistentes presentes na vacina antipneumocócica conjugada 7-valente, já licenciada. MÉTODOS: Foram identificados 19 casos de DPI entre pacientes HIV soropositivos com idade entre 1 mês e 20 anos hospitalizados de 1993 a 2000. Os dados foram registrados em fichas padronizadas, contendo informações sobre idade, diagnóstico clínico e evolução, sorotipos e perfil de sensibilidade para penicilina e ceftriaxona das cepas de Sp isoladas em cultura. Sp com concentração inibitória mínima < 0,1 mcg/mL foi considerado sensível à penicilina (SpSPn), e as demais cepas como não sensíveis (SpNSPn). RESULTADOS: Dos 19 casos de DPI em HIV soropositivos, 16 (84 por cento) tinham pneumonia e três (16 por cento), meningite; 13 (68 por cento) ocorreram em crianças menores de 2 anos e 16 (84 por cento) em menores de 5 anos. A letalidade foi de 10 por cento. Dos 13 casos em menores de 2 anos, sete (54 por cento) foram SpNSPn e 10 (77 por cento) foram causados por sorotipos contemplados na vacina antipneumocócica conjugada 7-valente. Foram isolados 10 sorotipos, sendo mais freqüentes o 14, 6B e 23F, todos sensíveis à ceftriaxona. Dos três casos de meningite, dois foram causados por SpNSPn. CONCLUSÃO: A maioria das DPI ocorreu em menores de 2 anos de idade; 77 por cento das cepas e 86 por cento dos sorotipos de SpNSPn estão contemplados pela vacina antipneumocócica conjugada 7-valente.


OBJECTIVE: Invasive pneumococcal disease (IPD) primarily affects children less than 5 years old, the elderly and certain at-risk groups; especially people infected by the human immunodeficiency virus (HIV). The objective of this study was to analyze invasive pneumococcal diseases (IPD) in children and adolescents infected by the human immunodeficiency virus (HIV), with relation to morbidity, the case fatality ratio, pneumococcus serotypes, susceptibility to penicillin and ceftriaxone and to the proportion of susceptible and resistant Streptococcus pneumoniae (Sp) included in the 7-valent pneumococcal conjugate vaccine that has already been licensed. METHODS: A total of 19 cases of IPD were identified among HIV seropositive patients aged from 1 month to 20 years and hospitalized between 1993 and 2000. Data were recorded on standardized charts containing information on age, clinical diagnosis and progression, serotypes and the susceptibility to penicillin and ceftriaxone of the Sp strains identified in cultures. When the minimum inhibitory concentration was < 0.1 mcg/mL, Sp were defined as susceptible to penicillin (SpSPn), and all other strains were defined as not susceptible (SpNSPn). RESULTS: Of the 19 HIV seropositive cases with IPD, 16 (84 percent) had pneumonia and three (16 percent), had meningitis; 13 (68 percent) cases were children less than 2 years old and 16 (84 percent) were less than 5 years old. The case fatality ratio was 10 percent. Seven (54 percent) of the 13 cases less than 2 years old were SpNSPn and 10 (77 percent) were caused by serotypes covered by the 7-valent pneumococcal conjugate vaccine. From the 10 isolated serotypes the most frequent were 14, 6B and 23F, all them susceptible to ceftriaxone. From the three patients with meningitis, two were caused by SpNSPn. CONCLUSION: In this study most of the IPD occurred in children less than 2 years old; 77 percent of the strains and 86 percent of the serotypes of SpNSPn...


Subject(s)
Adolescent , Adult , Child , Child, Preschool , Humans , Infant , Infant, Newborn , AIDS-Related Opportunistic Infections/microbiology , Meningitis, Pneumococcal/microbiology , Pneumonia, Pneumococcal/microbiology , Streptococcus pneumoniae , AIDS-Related Opportunistic Infections/mortality , Anti-Bacterial Agents/pharmacology , Ceftriaxone/pharmacology , Drug Resistance, Bacterial , Meningitis, Pneumococcal/mortality , Meningococcal Vaccines/immunology , Microbial Sensitivity Tests , Penicillins/pharmacology , Pneumococcal Vaccines/immunology , Pneumonia, Pneumococcal/mortality , Serotyping , Streptococcus pneumoniae/classification , Streptococcus pneumoniae/drug effects , Streptococcus pneumoniae/immunology
15.
Indian J Pathol Microbiol ; 2007 Jul; 50(3): 669-70
Article in English | IMSEAR | ID: sea-73428

ABSTRACT

Klebsiella pneumoniae has long been a prominent cause of nosocomial infections and outbreaks have been observed in the intensive care units and in high risk groups. We present here a brief report on an outbreak of Klebsiella pneumoniae which occurred in a neonatal intensive care unit in our teaching hospital. As neonates are at highest risk for acquisition of Klebsiella pneumoniae producing extended spectrum beta-lactamase, infection control policies and procedures should be strictly followed to prevent such outbreaks.


Subject(s)
Anti-Bacterial Agents/pharmacology , Cefotaxime/pharmacology , Ceftazidime/pharmacology , Ceftriaxone/pharmacology , Cephalosporin Resistance , Cross Infection/epidemiology , Disease Outbreaks , Hospitals, Teaching , Humans , India/epidemiology , Infant, Low Birth Weight , Infant, Newborn , Intensive Care Units, Neonatal , Klebsiella Infections/epidemiology , Klebsiella pneumoniae/classification , beta-Lactamases/biosynthesis
16.
J Health Popul Nutr ; 2007 Jun; 25(2): 158-67
Article in English | IMSEAR | ID: sea-547

ABSTRACT

Antimicrobial resistance of Shigella isolates in Bangladesh, during 2001-2002, was studied and compared with that of 1991-1992 to identify the changes in resistance patterns and trends. A significant increase in resistance to trimethoprim-sulphamethoxazole (from 52% to 72%, p < 0.01) and nalidixic acid (from 19% to 51%, p < 0.01) was detected. High, but unchanged, resistance to tetracycline, ampicillin, and chloramphenicol, low resistance to mecillinam (resistance 3%, intermediate 3%), and to emergence of resistance to azithromycin (resistance 16%, intermediate 62%) and ceftriaxone/cefixime (2%) were detected in 2001-2002. Of 266 recent isolates, 63% were resistant to > or =3 anti-Shigella drugs (multidrug-resistant [MDR]) compared to 52% of 369 strains (p < 0.007) in 1991-1992. Of 154 isolates tested by E-test in 2001-2002, 71% were nalidixic acid-resistant (minimum inhibitory concentration [MIC] > or =32 microg/mL) and had 10-fold higher MIC90 (0.25 microg/mL) to ciprofloxacin than that of nalidixic acid-susceptible strains exhibiting decreased ciprofloxacin susceptibility, which were detected as ciprofloxacin-susceptible and nalidixic acid-resistant by the disc-diffusion method. These strains were frequently associated with MDR traits. High modal MICs were observed to azithromycin (MIC 6 microg/mL) and nalidixic acid (MIC 128 micdrog/mL) and low to ceftriaxone (MIC 0.023 microg/mL). Conjugative R-plasmids-encoded extended-spectrum beta-lactamase was responsible for resistance to ceftriaxone/cefixime. The growing antimicrobial resistance of Shigella is worrying and mandates monitoring of resistance. Pivmecillinam or ciprofloxacin might be considered for treating shigellosis with caution.


Subject(s)
Anti-Bacterial Agents/pharmacology , Azithromycin/pharmacology , Bangladesh , Ceftriaxone/pharmacology , Ciprofloxacin/pharmacology , Colony Count, Microbial , Dose-Response Relationship, Drug , Drug Resistance, Bacterial , Drug Resistance, Multiple, Bacterial , Dysentery, Bacillary/drug therapy , Humans , Microbial Sensitivity Tests , Sentinel Surveillance , Shigella/drug effects , Species Specificity , Treatment Outcome
17.
Journal of Korean Medical Science ; : 791-794, 2007.
Article in English | WPRIM | ID: wpr-64223

ABSTRACT

The aim of this study was to investigate antimicrobial susceptibilities and macrolide resistance mechanisms of beta-hemolytic viridans group streptococci (VGS) in a tertiary Korean hospital. Minimum inhibitory concentrations (MICs) of seven antimicrobials were determined for 103 beta-hemolytic VGS isolated from various specimens. The macrolide resistance mechanisms of erythromycin-resistant isolates were studied by the double disk test and polymerase chain reaction (PCR). The overall resistance rates of beta-hemolytic VGS were found to be 47.5% to tetracycline, 3.9% to chloramphenicol, 9.7% to erythromycin, and 6.8% to clindamycin, whereas all isolates were susceptible to penicillin G, ceftriaxone, and vancomycin. Among ten erythromycin-resistant isolates, six isolates expressed a constitutive MLSB (cMLSB) phenotype, and each of the two isolates expressed the M phenotype, and the inducible MLSB (iMLSB) phenotype. The resistance rates to erythromycin and clindamycin of beta-hemolytic VGS seemed to be lower than those of non-beta-hemolytic VGS in our hospital, although cMLSB phenotype carrying erm(B) was dominant in beta-hemolytic VGS.


Subject(s)
Humans , Ceftriaxone/pharmacology , Chloramphenicol/pharmacology , Clindamycin/pharmacology , Cross Infection/genetics , Drug Resistance, Bacterial , Erythromycin/pharmacology , Immunoenzyme Techniques , Korea , Macrolides/pharmacology , Penicillin G/pharmacology , Phenotype , Polymerase Chain Reaction , Tetracycline/pharmacology , Vancomycin/pharmacology , Viridans Streptococci/genetics
18.
Medical Principles and Practice. 2006; 15 (2): 145-148
in English | IMEMR | ID: emr-79528

ABSTRACT

We evaluated ion exchange chromatography [IEC] on the Jeol Aminotac 500 analyzer for total homocysteine [tHcy] determination and compared it with an immunoassay method using fluorescence polarization on an Abbott IMx analyzer. IEC method validation [linearity, limit of detection, precision, interference] was made according to the French Biology Society guidelines [Societe Fran‡aise de Biologie Clinique]. Moreover, during a 2-month period, 55 plasma samples from patients scheduled for routine tHCy measurement were assayed by both methods for determining correlation. The IEC method was found linear up to at least 190 micro mol/l, and the limit of detection was 1.6 micro mol/l. Precision was studied with 3 controls at 6, 15 and 30 micro mol/l. Intra-assay coefficients of variation [n = 14] were 8.3, 3.1 and 2.3%, respectively, and inter-assay coefficients of variation [n = 15] were 9.6, 5.1 and 4.9%, respectively. No interference was found with other sulfur-containing amino acids [methionine, cysteine]. An excellent agreement was found between IEC and fluorescence polarization [Deming regression; y = 0.99x - 1.23; r = 0.97; p < 0.001]. The IEC method for tHcy measurement shows adequate precision and correlates highly with the IMx assay. The IEC method is more time-consuming but less expensive in reagent cost and allows simultaneous determination of plasma methionine concentration which may help to explain the underlying mechanism responsible for hyperhomocysteinemia


Subject(s)
Humans , Female , Gastroenteritis/drug therapy , Plasmids , Salmonella typhimurium/drug effects , Salmonella Infections/microbiology , Salmonella Infections/drug therapy , Ceftriaxone/pharmacology , Cephalosporin Resistance , Microbial Sensitivity Tests
19.
Article in English | IMSEAR | ID: sea-90173

ABSTRACT

AIMS: To study the in vitro activity of ceftriaxone alone and in combination with the beta-lactamase inhibitor tazobactam against bacterial isolates belonging to the Family Enterobacteriaceae. METHODS: One hundred and five consecutive isolates of Escherichia coli and Klebsiella spp. that had been recovered from various high-risk areas of the hospital were included in the study. MIC estimation to ceftriaxone and a combination of ceftriaxone and tazobactam was performed by the agar dilution method. RESULTS: By the MIC studies, 88.6% of the strains appeared to be resistant to ceftriaxone with the MIC90 value being > 256 microg/ml. When the MIC were done to ceftriaxone in combination with tazobactam, the resistance rate dropped to 4.8% with the MIC90 value being 4.0 microg/ml. CONCLUSION: The combination of ceftriaxone and tazobactam appears to be an excellent therapeutic alternative with 94.6% of ceftriaxone resistant strains being susceptible in vitro to this combination.


Subject(s)
Anti-Bacterial Agents/pharmacology , Ceftriaxone/pharmacology , Cephalosporins/pharmacology , Drug Therapy, Combination , Enterobacteriaceae/drug effects , Enzyme Inhibitors/pharmacology , Hospital Units , Microbial Sensitivity Tests , Penicillanic Acid/analogs & derivatives , beta-Lactamases/antagonists & inhibitors
20.
Article in English | IMSEAR | ID: sea-23881

ABSTRACT

BACKGROUND & OBJECTIVE: objectives: As antimicrobial susceptibility testing of Neisseria gonorrhoeae provides guidance for appropriate treatment, there is a need for simple, reliable and cost-effective method for susceptibility testing. The present study was aimed to compare the results of two methods of susceptibility testing, minimum inhibitory concentration (MIC) values by E test with disc diffusion results by Australian Gonococcal Surveillance Programme (AGSP) method in N. gonorrhoeae isolates. METHODS: Susceptibility testing for ciprofloxacin, penicillin and ceftriaxone using AGSP method was carried out for 301 confirmed consecutive isolates of N. gonorrhoeae. MIC of ciprofloxacin, penicillin and ceftriaxone was determined by E test in 301, 198 and 128 isolates respectively. The results of the two methods were compared by using Kappa statistics. RESULTS: Moderate levels of agreement for ciprofloxacin (kappa=0.44) and penicillin (kappa=0.54) were observed between the two methods. For ceftriaxone, 96.1 and 0.8 per cent isolates were found to be susceptible and less sensitive respectively by both the methods and per cent agreement between the two methods was 96.9 per cent. INTERPRETATION & CONCLUSION: Both the methods were easy to perform and gave reproducible results. However, disc diffusion method was cost-effective and more feasible in routine diagnostic laboratories in developing countries like India.


Subject(s)
Anti-Bacterial Agents/pharmacology , Anti-Infective Agents/pharmacology , Ceftriaxone/pharmacology , Ciprofloxacin/pharmacology , Humans , Male , Microbial Sensitivity Tests/methods , Neisseria gonorrhoeae/drug effects , Penicillins/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL